Full Press Release Details
Unlocking Life Changing Therapies September 2025 C O R PO R AT E O VER VI E W
RLMD Neutral Sentiment
Unlocking Life Changing Therapies September 2025 C O R PO R AT E O VER VI E W 2025 Relmada - All rights reserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - loo
Key Takeaway: The article provides an overview of Relmada's corporate strategies and future plans, specifically focusing on their therapies expected to unfold by September 2025. It emphasizes the potential for life-changing treatments that are being developed by the company. However, the text lacks specific details or insights into particular products or therapeutic areas under discussion.
Price reaction · baseline $1.6 (2025-09-16 close) · hit after-hours · clean, no other RLMD news in the window
day 0 close · peak
-5.6%
day 1
+3.1%
day 3
+3.1%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+97%
120-day peak, hindsight
Typical move
17.7%
average across 7 past catalysts
Cash runway
~68 mo
Minimal dilution risk
Lead asset
REL-1017
Phase 3 · Major Depressive Disorder
Frequently Asked Questions
What is the focus of the September 2025 Corporate Overview?
The focus is on unlocking life-changing therapies.
What date is associated with the Corporate Overview?
The Corporate Overview is from September 2025.
What is highlighted in the Corporate Overview document?
It highlights the development of transformative therapies.